Dr. Karl G. Csaky, MD
Ophthalmology (Ophthalmology Physician)
At a glance
- In the NPI registry since
- 2007
Licensed in Texas since 2009, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
TX license N3584 (first issued 2009; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 11 companies reported 33 payments worth $55,582 in total to this clinician.
| F. Hoffmann-la Roche AG | $11,059 |
|---|---|
| Boehringer Ingelheim International GmbH | $10,560 |
| Genentech, Inc. | $9,117 |
| Apellis Pharmaceuticals, Inc. | $7,193 |
| Biocryst Pharmaceuticals, Inc. | $5,263 |
| Astellas Pharma Europe LTD | $3,126 |
| Bausch & Lomb Americas Inc. | $3,048 |
| Genentech USA, Inc. | $3,017 |
| Consulting Fee | $46,732 |
|---|---|
| Travel and Lodging | $7,683 |
| Food and Beverage | $1,167 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genentech, Inc. Jun 16, 2025 | Consulting Fee | $9,000 |
| F. Hoffmann-la Roche AG Dec 8, 2025 | Consulting Fee | $7,497 |
| Apellis Pharmaceuticals, Inc. May 8, 2025 | Consulting Fee | $7,000 |
| Boehringer Ingelheim International GmbH Feb 14, 2025 | Travel and Lodging travel to Mainz, Germany · in-kind | $6,600 |
| Biocryst Pharmaceuticals, Inc. Sep 24, 2025 | Consulting Fee | $5,192 |
| Astellas Pharma Europe LTD Oct 13, 2025 | Consulting Fee Izervay · Ophthalmology | $3,126 |
| Bausch & Lomb Americas Inc. Oct 16, 2025 | Consulting Fee | $3,000 |
| Genentech USA, Inc. Apr 5, 2025 | Consulting Fee Vabysmo · Immunology and Ophthalmology | $2,995 |
| Boehringer Ingelheim International GmbH Feb 14, 2025 | Consulting Fee | $2,640 |
| Boehringer Ingelheim International GmbH Jan 22, 2025 | Consulting Fee | $1,320 |
All 19 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| F. Hoffmann-la Roche AG Dec 8, 2025 | Consulting Fee | $7,497 |
| F. Hoffmann-la Roche AG Dec 8, 2025 | Travel and Lodging travel to Basel, Switzerland | $798 |
| F. Hoffmann-la Roche AG Dec 8, 2025 | Travel and Lodging travel to Basel, Switzerland | $253 |
| F. Hoffmann-la Roche AG Dec 8, 2025 | Travel and Lodging travel to Basel, Switzerland | $32.56 |
| AbbVie Inc. Nov 4, 2025 | Consulting Fee OZURDEX · EYE CARE | $850 |
| Regeneron Pharmaceuticals, Inc. Oct 24, 2025 | Consulting Fee VEOPOZ · OPTHALMOLOGY, NEUROLOGY, HEMATOLOGY | $940 |
| Regeneron Pharmaceuticals, Inc. Oct 24, 2025 | Consulting Fee VEOPOZ · OPTHALMOLOGY, NEUROLOGY, HEMATOLOGY | $470 |
| Bausch & Lomb Americas Inc. Oct 16, 2025 | Consulting Fee | $3,000 |
| Astellas Pharma Europe LTD Oct 13, 2025 | Consulting Fee Izervay · Ophthalmology | $3,126 |
| Biocryst Pharmaceuticals, Inc. Sep 24, 2025 | Consulting Fee | $5,192 |
| Regeneron Pharmaceuticals, Inc. Jul 9, 2025 | Consulting Fee VEOPOZ · OPTHALMOLOGY, NEUROLOGY, HEMATOLOGY | $602 |
| Genentech, Inc. Jun 16, 2025 | Consulting Fee | $9,000 |
| Apellis Pharmaceuticals, Inc. May 8, 2025 | Consulting Fee | $7,000 |
| F. Hoffmann-la Roche AG May 4, 2025 | Consulting Fee | $1,260 |
| Genentech USA, Inc. Apr 5, 2025 | Consulting Fee Vabysmo · Immunology and Ophthalmology | $2,995 |
| Boehringer Ingelheim International GmbH Feb 14, 2025 | Travel and Lodging travel to Mainz, Germany · in-kind | $6,600 |
| Boehringer Ingelheim International GmbH Feb 14, 2025 | Consulting Fee | $2,640 |
| Boehringer Ingelheim International GmbH Jan 22, 2025 | Consulting Fee | $1,320 |
| F. Hoffmann-la Roche AG Jan 1, 2025 | Consulting Fee | $840 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 12 industry-funded studies in 2025, from 8 companies. The companies reported $1,239,350 in research payments for these studies, mostly to the institutions running them.
- A Randomized, Participant and Investigator Masked, Placebo-controlled, Multicenter, Proof-of-concept Study to Assess the Safety and Efficacy of LNP023 (Iptacopan) in Patients With Early and Intermediate Age-related Ma…
Novartis Pharmaceuticals Corporation - A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular dege…
Boehringer Ingelheim Pharmaceuticals, Inc. - Prospective assessment of virtual reality-based perimetry to measure retinal sensitivity in patients with non-neovascular (dry) age-related macular degeneration (amd)
Regeneron Pharmaceuticals, Inc. - A Phase 2, Double Masked, Placebo Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD)
Alexion Pharmaceuticals, Inc. - JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862
Boehringer Ingelheim Pharmaceuticals, Inc. - Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
AbbVie Inc. · Recruiting · NCT07160179 - A Prospective Non-interventional Study to Assess Novel Functional Endpoints in Geographic Atrophy and Normal-sighted Participants - No Compound
Janssen Research & Development, LLC - A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT06541704 - Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of ABBV-6628 in Subjects with Geographic Atrophy Secondary to Age-Related Macular Degeneration
AbbVie Inc. - IAMD Observational Study
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.